688366 昊海生科
已收盘 07-30 15:00:00
资讯
新帖
简况
昊海生科：与华润医药聚焦医美领域创新协作
证券之星 · 10:15
昊海生科：与华润医药聚焦医美领域创新协作
昊海生科：公司始终严格遵守信息披露法规
证券之星 · 10:09
昊海生科：公司始终严格遵守信息披露法规
昊海生科中标固原市药品采购项目 券商积极评价彰显发展潜力
自选股中标信息 · 07-29 11:12
昊海生科中标固原市药品采购项目 券商积极评价彰显发展潜力
2025年中国医疗美容市场供给分析：医美人才结构性短缺
前瞻产业研究院 · 07-29 06:00
2025年中国医疗美容市场供给分析：医美人才结构性短缺
昊海生科：累计耗资1,539.038万港元回购公司股份 比例达到0.26%
公司公告 · 07-28 09:25
昊海生科：累计耗资1,539.038万港元回购公司股份 比例达到0.26%
医疗耗材概念盘中拉升，爱博医疗涨7.09%
市场透视 · 07-24
医疗耗材概念盘中拉升，爱博医疗涨7.09%
2025年中国医美注射材料细分市场分析之医美注射类玻尿酸 2024年市场规模约125亿元【组图】
前瞻产业研究院 · 07-16
2025年中国医美注射材料细分市场分析之医美注射类玻尿酸 2024年市场规模约125亿元【组图】
多家跨国医疗巨头奔赴链博会，本土药械供应链再升级
第一财经 · 07-15
多家跨国医疗巨头奔赴链博会，本土药械供应链再升级
眼科医疗概念盘中跳水，国发股份跌1.07%
市场透视 · 07-15
眼科医疗概念盘中跳水，国发股份跌1.07%
巨头争相入局 竞逐千亿级医美赛道
中国产业经济信... · 07-12
巨头争相入局 竞逐千亿级医美赛道
【最全】2025年医美注射材料行业上市公司全方位对比（附业务布局汇总、业绩对比、业务规划等）
前瞻产业研究院 · 07-11
【最全】2025年医美注射材料行业上市公司全方位对比（附业务布局汇总、业绩对比、业务规划等）
价值研究所｜卷字号！医美玩家开始“资质卡位”了
中国基金报 · 07-08
价值研究所｜卷字号！医美玩家开始“资质卡位”了
医疗耗材概念盘中拉升，ST凯利涨4.29%
市场透视 · 07-08
医疗耗材概念盘中拉升，ST凯利涨4.29%
每周股票复盘：昊海生科（688366）调整回购价上限至88.72元并持续推进回购
证券之星 · 07-05
每周股票复盘：昊海生科（688366）调整回购价上限至88.72元并持续推进回购
华润系，官宣重磅合作
药智网 · 07-03
华润系，官宣重磅合作
中药行业报告：华润战略转型突破 从控股整合到生态主导
长城证券 · 07-02
中药行业报告：华润战略转型突破 从控股整合到生态主导
昊海生科：累计回购0.79%公司A股股份
格隆汇资讯 · 07-02
昊海生科：累计回购0.79%公司A股股份
2025年中国医美注射材料细分市场分析之医美注射类胶原蛋白 2024年市场规模约67亿元【组图】
前瞻产业研究院 · 07-01
2025年中国医美注射材料细分市场分析之医美注射类胶原蛋白 2024年市场规模约67亿元【组图】
昊海生科：与华润医药战略合作 将在医美领域建立“研发-生产-渠道”全链路合作
人民财讯 · 06-30
昊海生科：与华润医药战略合作 将在医美领域建立“研发-生产-渠道”全链路合作
每周股票复盘：昊海生科（688366）每股现金红利0.60元，股东减持计划披露
证券之星 · 06-29
每周股票复盘：昊海生科（688366）每股现金红利0.60元，股东减持计划披露
加载更多
公司概况
公司名称：
上海昊海生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2019-10-30
主营业务：
上海昊海生物科技股份有限公司的主营业务是医疗器械和药品研发、生产和销售。公司的主要产品是眼科粘弹剂、人工晶状体、视光材料、视光终端产品、玻尿酸、人表皮生长因子、射频及激光设备、玻璃酸钠注射液、医用几丁糖（关节腔注射用）、医用几丁糖（防粘连用）、医用透明质酸钠凝胶、胶原蛋白海绵。
发行价格：
89.23
{"stockData":{"symbol":"688366","market":"SH","secType":"STK","nameCN":"昊海生科","latestPrice":54.52,"timestamp":1753858800000,"preClose":54.96,"halted":0,"volume":1415516,"delay":0,"changeRate":-0.008,"floatShares":194000000,"shares":233000000,"eps":1.7767,"marketStatus":"已收盘","change":-0.44,"latestTime":"07-30 15:00:00","open":54.8,"high":55.42,"low":53.89,"amount":77669900,"amplitude":0.0278,"askPrice":54.52,"askSize":40,"bidPrice":54.43,"bidSize":2,"shortable":0,"etf":0,"ttmEps":1.7767,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753925400000},"marketStatusCode":5,"adr":0,"adjPreClose":54.96,"symbolType":"stock_kcb","openAndCloseTimeList":[[1753839000000,1753846200000],[1753851600000,1753858800000]],"highLimit":60.46,"lowLimit":49.46,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":232581095,"isCdr":false,"pbRate":2.24,"roa":"--","peRate":30.686103,"roe":"1.61%","epsLYR":1.8,"committee":-0.2,"marketValue":12680000000,"turnoverRate":0.0073,"status":1,"afterMarket":{"amount":0,"volume":0,"close":54.52,"buyVolume":0,"sellVolume":200,"time":1753860838019,"indexStatus":"已收盘 07-30 15:30:00","preClose":54.96},"hkstockBrief":{"symbol":"06826","market":"HK","secType":"STK","nameCN":"昊海生物科技","latestPrice":29.1,"timestamp":1753862888519,"preClose":29.75,"halted":0,"volume":766700,"delay":0,"premium":"-51.07"},"floatMarketCap":10580000000},"requestUrl":"/m/hq/s/688366","defaultTab":"news","newsList":[{"id":"2555017014","title":"昊海生科：与华润医药聚焦医美领域创新协作","url":"https://stock-news.laohu8.com/highlight/detail?id=2555017014","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555017014?lang=zh_cn&edition=full","pubTime":"2025-07-30 18:15","pubTimestamp":1753870522,"startTime":"0","endTime":"0","summary":"证券之星消息，昊海生科07月30日在投资者关系平台上答复投资者关心的问题。公司与华润医药将聚焦医美领域创新协作，共拓中国医美产业新蓝海。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025073000031527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","03320","688366","BK1191","BK1570","BK0251"],"gpt_icon":0},{"id":"2555017488","title":"昊海生科：公司始终严格遵守信息披露法规","url":"https://stock-news.laohu8.com/highlight/detail?id=2555017488","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555017488?lang=zh_cn&edition=full","pubTime":"2025-07-30 18:09","pubTimestamp":1753870156,"startTime":"0","endTime":"0","summary":"证券之星消息，昊海生科07月30日在投资者关系平台上答复投资者关心的问题。公司始终严格遵守信息披露法规，确保所有法定披露信息通过上交所、香港联交所网站等官方渠道及时发布，并通过业绩说明会、上证e互动、投资者热线、电子邮箱等多种渠道积极与投资者互动交流。公司将持续做好投资者关系管理，在合规前提下加强公司价值传递。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025073000031460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0251","688366"],"gpt_icon":0},{"id":"2555555580","title":"昊海生科中标固原市药品采购项目 券商积极评价彰显发展潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2555555580","media":"自选股中标信息","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555555580?lang=zh_cn&edition=full","pubTime":"2025-07-29 19:12","pubTimestamp":1753787535,"startTime":"0","endTime":"0","summary":"2025年07月29日，据天眼查数据，固原市第一批公立医疗机构阳光挂网药品联合二次议价采购中选结果公示公告显示，中标方为昊海生科，招标方为固原市药耗联合二次议价工作领导小组。近半年内，昊海生科获得4家券商积极评价：东吴证券和中信建投证券给予\"买入\"评级。昊海生科主营业务涵盖医疗美容与创面护理产品，眼科产品，骨科产品，其他收入之和。截至发稿，昊海生科股价报54.96元，上涨1.27%，成交额至7354.73万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729191225a6c7bf34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729191225a6c7bf34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0251","688366"],"gpt_icon":0},{"id":"2555874087","title":"2025年中国医疗美容市场供给分析：医美人才结构性短缺","url":"https://stock-news.laohu8.com/highlight/detail?id=2555874087","media":"前瞻产业研究院","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555874087?lang=zh_cn&edition=full","pubTime":"2025-07-29 14:00","pubTimestamp":1753768804,"startTime":"0","endTime":"0","summary":"大会首发的《2024年整形美容人才就业数据分析报告》数据显示，全国医美机构从业人员总数约为102万人，合规医生缺口2万人左右。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507291405489724b8ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507291405489724b8ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688366","688363","BK0229"],"gpt_icon":0},{"id":"2554778369","title":"昊海生科：累计耗资1,539.038万港元回购公司股份 比例达到0.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554778369","media":"公司公告","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554778369?lang=zh_cn&edition=full","pubTime":"2025-07-28 17:25","pubTimestamp":1753694731,"startTime":"0","endTime":"0","summary":"昊海生科公告，2024年12月5日至2025年5月12日期间，公司已实际回购H股股份61.26万股，占公司总股本的0.26%，使用资金总额1,539.038万港元（不含交易税费）。本次回购的股份已全部注销，公司总股本由23319.37万股变更为23258.11万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728173130a6c5b753&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728173130a6c5b753&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","BK0239","688366"],"gpt_icon":0},{"id":"2553275919","title":"医疗耗材概念盘中拉升，爱博医疗涨7.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553275919","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553275919?lang=zh_cn&edition=full","pubTime":"2025-07-24 13:19","pubTimestamp":1753334393,"startTime":"0","endTime":"0","summary":"07月24日，医疗耗材概念盘中拉升，截至13点19分，医疗耗材概念整体指数上涨1.05%，报1186.380点。从个股上来看，该概念的成分股中，爱博医疗涨7.09%，昊海生科、红日药业、威高骨科涨幅居前。从资金上来看，截止发稿，医疗耗材概念概念主力净流入为-5.13亿，其中爱博医疗受到资金热捧，主力净流入2554.66万；拉长时间线来看，该板块近20日主力资金净流入-2.47亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724131953971b48da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724131953971b48da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2460026573.USD","BK0251","688050","688161","688366","159891"],"gpt_icon":0},{"id":"2551114813","title":"2025年中国医美注射材料细分市场分析之医美注射类玻尿酸 2024年市场规模约125亿元【组图】","url":"https://stock-news.laohu8.com/highlight/detail?id=2551114813","media":"前瞻产业研究院","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551114813?lang=zh_cn&edition=full","pubTime":"2025-07-16 12:00","pubTimestamp":1752638441,"startTime":"0","endTime":"0","summary":"2、医美注射类玻尿酸市场规模玻尿酸是最早规模化应用的医美注射材料，消费者认知度，2024年，我国医美注射类玻尿酸市场规模约125亿元，同比增长21.4%，2021-2024年CAGR为25.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716120609954458bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716120609954458bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","02367","BK0229","BK0239","688366","688363","300896"],"gpt_icon":0},{"id":"2551662190","title":"多家跨国医疗巨头奔赴链博会，本土药械供应链再升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2551662190","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551662190?lang=zh_cn&edition=full","pubTime":"2025-07-16 00:15","pubTimestamp":1752596100,"startTime":"0","endTime":"0","summary":"第一财经记者获悉，即将于7月16日开幕的第三届中国国际供应链促进博览会，包括美敦力、阿斯利康、GE医疗等跨国医疗巨头确认参展。美敦力方面介绍，今年是该公司首次参加链博会，并将展示一款全新的由美敦力中国研发中心和本土临床专家合作的起搏心脏导管研发成果。在本届链博会上，阿斯利康国际市场供应链管理高级执行总裁Steven Rota也将发表主旨演讲。阿斯利康已连续第三年参加链博会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716062402a44d2312&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716062402a44d2312&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688298","688366","688576","688161","688139","688068","688580","159891","688013","688029","688606","688389","688050","688317","688575","688271","600645","688108","603014","688358","688426","688617","688677","605369","688217","603205","603301","688114","688314","688273","688253","688338","BK0239","603987","688613","688016","688198","688212","603387","603976","688026","688085","600807","688075","688393","688607","603309","688626","688755","688236","603222","688468","688767","603658","603880","688067","688581","688656","600529","688351","688410","688151","688193","688289","688399","600587","600055","688301"],"gpt_icon":0},{"id":"2551413067","title":"眼科医疗概念盘中跳水，国发股份跌1.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551413067","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551413067?lang=zh_cn&edition=full","pubTime":"2025-07-15 10:33","pubTimestamp":1752546781,"startTime":"0","endTime":"0","summary":"07月15日，眼科医疗概念盘中跳水，截至10点32分，眼科医疗概念整体指数下跌2.04%，报1356.220点。从个股上来看，该概念的成分股中，国发股份跌1.07%，昊海生科、爱尔眼科、鱼跃医疗跌幅居前。从资金上来看，截止发稿，眼科医疗概念主力净流入为-2.85亿，其中爱尔眼科受到资金热捧，主力净流入1728.77万；拉长时间线来看，该板块近20日主力资金净流入-21.62亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071510330197a66e62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071510330197a66e62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688366","BK0251","BK0102","BK0250","BK0077","600538"],"gpt_icon":0},{"id":"2551914254","title":"巨头争相入局 竞逐千亿级医美赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2551914254","media":"中国产业经济信...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551914254?lang=zh_cn&edition=full","pubTime":"2025-07-13 00:00","pubTimestamp":1752336000,"startTime":"0","endTime":"0","summary":"近段时间，接连有医药企业、跨界大佬争相“杀入”医美赛道。两项交易总额达34亿元。此次权益变动后，养生堂和杭州久视合计持有锦波生物股份占比超过10%。数据显示，2025年第一季度，锦波生物实现营业收入3.66亿元，同比增长62.51%。同时，华熙生物与巨子生物的玻尿酸与重组胶原蛋白之争，则反映出医美产品快速迭代带来的竞争加剧。针对近期媒体曝光的医美领域乱象，公安部表明将采取有力措施，严厉打击相关违法犯罪活动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071307104497a3e1d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071307104497a3e1d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0146","BK0012","BK0201","600998","BK0097","BK0028","688363","BK0077","688366","BK0196","BK0187","BK0039","BK0188","BK0183","603392","BK0250"],"gpt_icon":0},{"id":"2550609029","title":"【最全】2025年医美注射材料行业上市公司全方位对比（附业务布局汇总、业绩对比、业务规划等）","url":"https://stock-news.laohu8.com/highlight/detail?id=2550609029","media":"前瞻产业研究院","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550609029?lang=zh_cn&edition=full","pubTime":"2025-07-11 10:00","pubTimestamp":1752199206,"startTime":"0","endTime":"0","summary":"3、医美注射材料上市企业业务布局对比当前，中国医美注射材料上市公司中，爱美客和巨子生物医美注射材料产品市场表现出色，2024年爱美客医美注射材料销售额约29.60亿元，巨子生物医美注射材料销售额约55.20亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071110520897a1b9a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071110520897a1b9a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688363","688366","510620","BK0229","02367"],"gpt_icon":0},{"id":"2549591602","title":"价值研究所｜卷字号！医美玩家开始“资质卡位”了","url":"https://stock-news.laohu8.com/highlight/detail?id=2549591602","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549591602?lang=zh_cn&edition=full","pubTime":"2025-07-08 12:46","pubTimestamp":1751950009,"startTime":"0","endTime":"0","summary":"药企抢滩医美赛道，美妆企业展开“械字号”竞争，行业变革的关键时刻或将到来中国基金报记者赵心怡医美领域不断有新玩家“上桌”。年报显示，2024年九州通医美板块的合作医美服务机构达10560家，同比增长84.81%。华润医药与昊海生科合作，构建“研产销”闭环生态。“械字号”与“妆字号”不同，需要国家药监局的批准注册，同时要具有治疗或辅助治疗的作用。庞大的市场需求促使美妆企业们跃跃欲试，纷纷涌入“械字号”这一领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708125225a43d36b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708125225a43d36b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0183","BK0196","BK0039","BK0188","BK0028","688366","02367","BK0146","BK0077","BK0012","BK0250","02607","BK0201","BK0097","600998","BK0187"],"gpt_icon":0},{"id":"2549567274","title":"医疗耗材概念盘中拉升，ST凯利涨4.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549567274","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549567274?lang=zh_cn&edition=full","pubTime":"2025-07-08 09:36","pubTimestamp":1751938560,"startTime":"0","endTime":"0","summary":"07月08日，医疗耗材概念盘中拉升，截至09点35分，医疗耗材概念整体指数上涨0.61%，报1111.780点。从个股上来看，该概念的成分股中，ST凯利涨4.29%，乐普医疗、塞力医疗、昊海生科涨幅居前。从资金上来看，截止发稿，医疗耗材概念概念主力净流入为-3429.51万，其中九州通受到资金热捧，主力净流入165.40万；拉长时间线来看，该板块近20日主力资金净流入-11.76亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708093600953a33ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708093600953a33ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","688366","BK0039","BK0028","BK0250","BK0077","BK0146","BK0187","BK0201","BK0251","BK0097","603716","600998","159891","BK0196","300326","BK0183","BK0188"],"gpt_icon":0},{"id":"2549328843","title":"每周股票复盘：昊海生科（688366）调整回购价上限至88.72元并持续推进回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2549328843","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549328843?lang=zh_cn&edition=full","pubTime":"2025-07-06 07:23","pubTimestamp":1751757789,"startTime":"0","endTime":"0","summary":"截至2025年7月4日收盘，昊海生科报收于50.41元，较上周的50.75元下跌0.67%。本周，昊海生科6月30日盘中最高价报51.54元。本周关注点公司公告汇总：昊海生科调整回购A股股份价格上限至88.72元/股，自2025年6月30日起生效。公司公告汇总：截至2025年6月30日，昊海生科累计已回购股数1,832,421股，占总股本比例0.79%，累计已回购金额10,390.54万元。H股公告上海昊海生物科技股份有限公司提交了截至2025年6月30日的证券变动月报表。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070600001059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0251","688366"],"gpt_icon":0},{"id":"2548847206","title":"华润系，官宣重磅合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2548847206","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548847206?lang=zh_cn&edition=full","pubTime":"2025-07-03 09:49","pubTimestamp":1751507340,"startTime":"0","endTime":"0","summary":"华润医药与昊海生科正式签署战略合作协议，宣布将强强联手，在医美领域开启深度创新协作之旅。借助昊海生科在生物材料研发方面的专业积累和华润医药在医药领域的丰富经验，有望在医美技术创新方面取得重大突破，开发出更具竞争力和市场吸引力的产品。对于华润医药来说，昊海生科的加盟为其医美业务布局注入了强大的活力。在行业层面，华润医药与昊海生科的合作将起到积极的示范作用，推动医美行业的资源整合和协同发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703095054a4cc3384&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703095054a4cc3384&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01109","688366","03320","BK0251","BK0239"],"gpt_icon":0},{"id":"2548822094","title":"中药行业报告：华润战略转型突破 从控股整合到生态主导","url":"https://stock-news.laohu8.com/highlight/detail?id=2548822094","media":"长城证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548822094?lang=zh_cn&edition=full","pubTime":"2025-07-03 00:00","pubTimestamp":1751472000,"startTime":"0","endTime":"0","summary":"事件：2025 年6 月26 日，上海昊海生物科技股份有限公司与华润医药集团有限公司“聚势未来、扬帆起航”战略合作签约仪式于昊海生科国际医药研发及产业化基地正式举行：双方宣布将深度融合研发力与渠道力，聚焦医美领域创新协作，共拓中国医美产业新蓝海。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703140455a4cc9e1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703140455a4cc9e1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0175","BK0028","600750","BK0239","688366","600422"],"gpt_icon":0},{"id":"2548898899","title":"昊海生科：累计回购0.79%公司A股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2548898899","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548898899?lang=zh_cn&edition=full","pubTime":"2025-07-02 17:31","pubTimestamp":1751448665,"startTime":"0","endTime":"0","summary":"格隆汇7月2日丨昊海生科(688366.SH)公布，截至2025年6月30日，公司通过集中竞价交易方式累计回购公司A股股份1,832,421股，占公司总股本的比例为0.79%，最高成交价为63.58元/股，最低成交价为49.25元/股，成交总金额为103,905,394.55元（不含印花税、交易佣金等交易费用）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507021731179533be7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"671b7a6380a11f784a7354783e5480b0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507021731179533be7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","BK0239","159982","399300","688366"],"gpt_icon":0},{"id":"2548747030","title":"2025年中国医美注射材料细分市场分析之医美注射类胶原蛋白 2024年市场规模约67亿元【组图】","url":"https://stock-news.laohu8.com/highlight/detail?id=2548747030","media":"前瞻产业研究院","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548747030?lang=zh_cn&edition=full","pubTime":"2025-07-01 16:00","pubTimestamp":1751356857,"startTime":"0","endTime":"0","summary":"2、医美注射类胶原蛋白市场规模胶原蛋白是人体自身存在的物质，与人体组织的相容性高，不易引起排异反应和过敏现象，2024年，我国医美注射类胶原蛋白市场规模约67亿元，同比增长21.8%，2021-2024年CAGR为21.9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507011705429795b0e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507011705429795b0e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688363","02367","BK0239","BK0229","300896","688366","BK0251"],"gpt_icon":0},{"id":"2547305665","title":"昊海生科：与华润医药战略合作 将在医美领域建立“研发-生产-渠道”全链路合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2547305665","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547305665?lang=zh_cn&edition=full","pubTime":"2025-06-30 13:23","pubTimestamp":1751261016,"startTime":"0","endTime":"0","summary":"昊海生科(688366)今日官微消息，近日，昊海生科与华润医药集团战略合作签约仪式正式举行，双方宣布将聚焦医美领域创新协作，拓展中国医美产业新蓝海。华润医药将充分发挥其千亿级渠道网络优势，加速昊海生科核心产品的临床价值转化与市场覆盖率，将建立“研发-生产-渠道”全链路合作体系。资料显示，华润医药是国内第一大非处方药（OTC）制造商，业务网络覆盖全国28个省级区域。文章来源：人民财讯原标题：昊海生科：与华润医药战略合作 将在医美领域建立“研发-生产-渠道”全链路合作","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630132950a7254863&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630132950a7254863&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0251","688366","03320"],"gpt_icon":0},{"id":"2547704197","title":"每周股票复盘：昊海生科（688366）每股现金红利0.60元，股东减持计划披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2547704197","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547704197?lang=zh_cn&edition=full","pubTime":"2025-06-29 08:02","pubTimestamp":1751155342,"startTime":"0","endTime":"0","summary":"截至2025年6月27日收盘，昊海生科报收于50.75元，较上周的49.45元上涨2.63%。公司总股本为233,193,695股，扣除回购专用证券账户中股份数4,460,695股，合计拟派发现金红利137,239,800.00元。其他机构投资者和法人股东每股实际派发现金红利为税前人民币0.60元。公司累计回购A股股份3848095股，占总股本233193695股的1.65%。上海昊海生物科技股份有限公司还发布了股东减持股份计划公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062900001414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688366","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753881382116,"stockEarnings":[{"period":"1week","weight":0.0313},{"period":"1month","weight":0.0956},{"period":"3month","weight":0.0605},{"period":"6month","weight":-0.0296},{"period":"1year","weight":-0.0257},{"period":"ytd","weight":-0.0821}],"compareEarnings":[{"period":"1week","weight":0.0078},{"period":"1month","weight":0.0542},{"period":"3month","weight":0.1008},{"period":"6month","weight":0.1105},{"period":"1year","weight":0.2482},{"period":"ytd","weight":0.077}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海昊海生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"2019-10-30","address":"上海市松江区松江工业区洞泾路5号","registeredCapital":"23258万元","survey":" 上海昊海生物科技股份有限公司的主营业务是医疗器械和药品研发、生产和销售。公司的主要产品是眼科粘弹剂、人工晶状体、视光材料、视光终端产品、玻尿酸、人表皮生长因子、射频及激光设备、玻璃酸钠注射液、医用几丁糖（关节腔注射用）、医用几丁糖（防粘连用）、医用透明质酸钠凝胶、胶原蛋白海绵。","listedPrice":89.23},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昊海生科(688366)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昊海生科(688366)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昊海生科,688366,昊海生科股票,昊海生科股票老虎,昊海生科股票老虎国际,昊海生科行情,昊海生科股票行情,昊海生科股价,昊海生科股市,昊海生科股票价格,昊海生科股票交易,昊海生科股票购买,昊海生科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昊海生科(688366)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昊海生科(688366)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}